Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Preleukemia 1Polycythemia Vera 1Neoplasm, Residual 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Diseases 1

Interventions

venetoclax 1spartalizumab 1sabatolimab 1ruxolitinib 1lintuzumab 1filanesib 1Lenalidomide 1Decitabine 1CPI-0610 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Preleukemia × sabatolimab × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡